Incidence and spectrum of yeast species isolated from the oral cavity of Iranian patients suffering from hematological malignancies

References

• Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int. 2013;2013:204237.
   PubMed Web of Science ®Google Scholar
• Gauwerky K, Borelli C, Korting HC. Targeting virulence: a new paradigm for antifungals. Drug Discov Today. 2009;14(3–4):214–9.
   PubMed Web of Science ®Google Scholar
• Gow NA, Netea MG. Medical mycology and fungal immunology: new research perspectives addressing a major world health challenge. Philos Trans R Soc Lond B Biol Sci. 2016;371(1709):20150462.
   Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010;18(8):985–992.
   PubMed Web of Science ®Google Scholar
• Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis. 2005;11(5):268–273.
   PubMed Web of Science ®Google Scholar
• Raber-Durlacher JE, Barasch A, Peterson DE, et al. Oral complications and management considerations in patients treated with high-dose chemotherapy. Support Cancer Ther. 2004;1(4):219–229.
   Google Scholar
• Hamza OJ, Matee MI, Brüggemann RJ, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis. 2008;47(10):1270–1276.
   PubMed Web of Science ®Google Scholar
• Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV‐infected patients on highly active antiretroviral therapy. HIV Med. 2004;5(1):50–54.
   PubMed Web of Science ®Google Scholar
• Koo S, Kejariwal D, Al-Shehri T,et al. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation. United European. Gastroenterol J. 2017;5(5):625–631.
   Google Scholar
• Mosel DD, Bauer RL, Lynch DP, et al. Oral complications in the treatment of cancer patients. Oral Dis. 2011;17:550–559.
   PubMed Web of Science ®Google Scholar
• Jan A, Bashir G, Fomda BA, et al. Molecular identification of Candida dubliniensis among Candida albicans isolated from oral cavity of cancer patients using PCR-RFLP, in a tertiary care hospital in Kashmir, India. Br Microbiol Res J. 2016;14:2.
   Google Scholar
• Lamoth F, Lockhart SR, Berkow EL, et al. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):4–13.
   PubMed Web of Science ®Google Scholar
• Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2017;7:2173.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 2014;27(6):484–492.
   PubMed Web of Science ®Google Scholar
• Murray PR. What is new in clinical microbiology—microbial identification by MALDI-TOF mass spectrometry: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn. 2012;14(5):419–423.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Azim A, Baronia AK, et al. Invasive candidiasis in non neutropenic critically ill-need for region-specific management guidelines. Indian J Crit Care Med. 2015;19(6):333–339.
   Web of Science ®Google Scholar
• Rajkumari N, Mathur P, Xess I, et al. Distribution of different yeasts isolates among trauma patients and comparison of accuracy in identification of yeasts by automated method versus conventional methods for better use in low resource countries. Indian J Med Microbiol. 2014;32(4):391–397.
   Web of Science ®Google Scholar
• Wong G, Wong I, Chan K, et al. A rapid and low-cost PCR thermal cycler for low resource settings. PLoS One. 2015;10(7):e0131701.
   Web of Science ®Google Scholar
• Ragheb SM, Jimenez L. Polymerase chain reaction/rapid methods are gaining a foothold in developing countries. PDA J Pharm Sci Technol. 2014 May 6;68(3):239–255.
   Google Scholar
• Arastehfar A, Fang W, Pan W, et al. YEAST PANEL Multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. Diagn Microbiol Infect Dis. 2019;93(2):112–119.
   Web of Science ®Google Scholar
• Khedri S, Santos ALS, Roudbary M, et al. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. Lett Appl Microbiol. 2018;67(4):392–399.
   PubMed Web of Science ®Google Scholar
• Jahanshiri Z, Manifar S, Moosa H et al. Oropharyngeal candidiasis in head and neck cancer patients in Iran: Species identification, antifungal susceptibility and pathogenic characterization. J Mycol Med. 2018;28(2):361–366.
   PubMed Web of Science ®Google Scholar
• Katiraee F, Khosravi AR, Khalaj V, et al. Oropharyngeal candidiasis and oral yeast colonization in Iranian Human Immunodeficiency Virus positive patients. J Mycol Med. 2010; 1:20(1):8–14.
   Google Scholar
• Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002;78(922):455–459.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52(1):61–77.
   PubMedGoogle Scholar
• Dufresne SF, Marr KA, Sydnor E, et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol. 2014;52(6):1830–1837.
   Web of Science ®Google Scholar
• Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(7):882–913.
   PubMed Web of Science ®Google Scholar
• Cassagne C, Cella AL, Suchon P, et al. Evaluation of four pretreatment procedures for MALDI-TOF MS yeast identification in the routine clinical laboratory. Med Mycol. 2013;51(4):371–377.
   Web of Science ®Google Scholar
• Theelen B, Silvestri M, Guého E, et al. Identification and typing of Malassezia yeasts using amplified fragment length polymorphism (AFLPTm), random amplified polymorphic DNA (RAPD) and denaturing gradient gel electrophoresis (DGGE). FEMS Yeast Res. 2001;1(2):79–86.
   Web of Science ®Google Scholar
• Stielow JB, Lévesque CA, Seifert KA, et al. One fungus, which genes? Development and assessment of universal primers for potential secondary fungal DNA barcodes. Persoonia. 2015;35:242–263.
   PubMed Web of Science ®Google Scholar
• Romeo O, Racco C, Criseo G. Amplification of the hyphal wall protein 1 gene to distinguish Candida albicans from Candida dubliniensis. J Clin Microbiol. 2006;44(7):2590–2592.
   Web of Science ®Google Scholar
• Marchetta A, Gerrits van Den Ende B, Al-Hatmi AMS, et al. Global molecular diversity of the halotolerant fungus Hortaea werneckii. Life (Basel). 2018 23;8(3):31.
   Web of Science ®Google Scholar
• Alexander BD, Procop GW, Dufresne P, et al. Reference method for broth dilution antifungal susceptibility testing of teasts (M27-S4). Clin Lab Stand Inst. 2017;37:1–33.
   Google Scholar
• Pfaller M, Diekema D. Progress in antifungal susceptibility testing of Candida spp. using clinical and laboratory standards institute broth microdilution methods, 2010–2012. J Clin Microbiol. 2012;50(9):2846–2856.
   Web of Science ®Google Scholar
• Fanello S, Bouchara JP, Jousset N, et al. Nosocomial Candida albicans acquisition in a geriatric unit: epidemiology and evidence for person-to-person transmission. J Hosp Infect. 2001;47(1):46–52.
   Web of Science ®Google Scholar
• Gautam H, Kaur R, Goyal R, et al. Oral thrush to candidemia: A morbid outcome. J Int Assoc Physicians AIDS Care (Chic). 2010; 9(5):325–327.
   Google Scholar
• Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8(3):352–358.
   Web of Science ®Google Scholar
• Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–128.
   PubMed Web of Science ®Google Scholar
• Aslani N, Janbabaei G, Abastabar M, et al. Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infect Dis. 2018;18(1):24.
   PubMed Web of Science ®Google Scholar
• Hamzehee S, Kalantar-Neyestanaki D, Mohammadi MA, et al. Identification of Candida spp. isolated from oral mucosa in patients with leukemias and lymphomas in Iran. Iran J Microbiol. 2019;11(2):114–119.
   Google Scholar
• Jayachandran AL, Katragadda R, Thyagarajan R, et al. Oral candidiasis among cancer patients attending a tertiary Care Hospital in Chennai, South India: an evaluation of clinicomycological association and antifungal susceptibility pattern. Can J Infect Dis Med Microbiol. 2016;2016:8758461.
   Web of Science ®Google Scholar
• Sendid B, Lacroix C, Bougnoux ME. Is Candida kefyr an emerging pathogen in patients with oncohematological diseases? Clin Infect Dis. 2006 1;43(5):666–667.
   Web of Science ®Google Scholar
• Eddouzi J, Lohberger A, Vogne C, et al. Identification and antifungal susceptibility of a large collection of yeast strains isolated in Tunisian hospitals. Med Mycol. 2013;51(7):737–746.
   Web of Science ®Google Scholar
• Katiraee F, Khosravi A, Khalaj V, et al. Oral candidiasis in Human Immunodeficiency Virus (HIV) infected individuals in Iran. Tum J. 2010;68(1):37–44.
   Google Scholar
• Azizi A, Rezaei M. Prevalence of Candida species in the oral cavity of patients undergoing head and neck radiotherapy. J Dent Res Dent Clin Dent Prospects. 2009;3(3):78–81.
   Google Scholar
• Katiraee F, Teifoori F, Soltani M. Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran. Curr Med Mycol. 2015;1(3):11–16.
   Google Scholar
• Jabalameli Z, Sabzghabaee AM, Mohaghegh MA, et al. Antifungal susceptibility of Candida species isolated from cancer patients with oral lesions undergoing chemotherapy. Int J Infect. 2017;4(4):e14178.
   Google Scholar
• Vallès Y, Inman CK, Peters BA, et al. Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study. Sci Rep. 2018 27;8(1):11327.
   Web of Science ®Google Scholar
• Willis JR, González-Torres P, Pittis AA, et al. Citizen science charts two major “stomatotypes” in the oral microbiome of adolescents and reveals links with habits and drinking water composition. Microbiome. 2018;6(1):218.
   Web of Science ®Google Scholar
• Lyu X, Zhao C, Yan ZM, et al. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1161–1171.
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev. 2002;4:CD002033.
   PubMedGoogle Scholar
• Garcia-Cuesta C, Sarrion-Pérez MG, Bagán JV. Current treatment of oral candidiasis: a literature review. J Clin Exp Dent. 2014;6(5):e576–e582.
   PubMedGoogle Scholar
• de Wet N, Llanos-Cuentas A, Suleiman J. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842–849.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xiao M, Watts MR. Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy. BMC Infect Dis. 2015;15:340.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54(8):3149–3154.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lockhart SR, Najvar LK, et al. The fungal Cyp51 specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2018;63(3): 02233–18.
   Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Garvey EP, et al. The fungal Cyp51 inhibitor VT-1129 is efficacious in an experimental model of cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62(9):e01071–18.
   PubMed Web of Science ®Google Scholar
• Shubitz LF, Roy ME, Trinh HT, et al. Efficacy of the investigational antifungal VT-1161 in treating naturally occurring coccidioidomycosis in dogs. Antimicrob Agents Chemother. 2017;61(5): e00111–17.
   Web of Science ®Google Scholar
• Broyer P, Perrot N, Rostaing H, et al. An Automated Sample Preparation Instrument To Accelerate Positive Blood Cultures Microbial Identification by MALDI-TOF Mass Spectrometry (Vitek® MS). Front Microbiol. 2018;9:911.
   PubMed Web of Science ®Google Scholar
• de Luna, F.F.-Á., Use of MALDI-TOF Mass Spectrometry in Fungal Diagnosis, in The Use of Mass Spectrometry Technology (MALDI-TOF) in Clinical Microbiology. 2018; 197-211.
   Google Scholar
• Asadzadeh M, Ahmad S, Al-Sweih N, et al. Molecular fingerprinting studies do not support intrahospital transmission of Candida albicans among candidemia patients in Kuwait. Frontiers in microbiology. Front Microbiol. 2017;8:247.
   Web of Science ®Google Scholar